Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine.

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is characterized by a distinct immunophenotype (CD1a-negative, CD8-negative, CD5-negative or weak-positive <75%, myeloid/stem-cell markers positive) and poor clinical outcomes. Near-ETP ALL is transcriptionally similar to ETP-ALL but CD5 expression level is not low enough to meet the criteria of ETP immunophenotype. Outcomes of near-ETP ALL are not well characterized. We reviewed 171 patients with newly-diagnosed T-ALL/LBL. Patients were categorized into three groups; ETP (N=27), near-ETP (N=24), and non-ETP ALL/LBL (N=120). ETP-ALL/LBL was associated with a significantly worse survival compared with non-ETP ALL/LBL: 5-year overall survival (OS) rates 32% versus 63% (p

View the full article @ American journal of hematology

Get PDF with LibKey
Authors: Kiyomi Morita, Nitin Jain, Hagop Kantarjian, Koichi Takahashi, Hong Fang, Marina Konopleva, Siba El Hussein, Feng Wang, Nicholas J Short, Abhishek Maiti, Koji Sasaki, Guillermo Garcia-Manero, Sergej Konoplev, Farhad Ravandi, Joseph D Khoury, Elias Jabbour